[go: up one dir, main page]

WO2019171352A3 - Methods of treating severe non-diabetic obesity - Google Patents

Methods of treating severe non-diabetic obesity Download PDF

Info

Publication number
WO2019171352A3
WO2019171352A3 PCT/IB2019/051915 IB2019051915W WO2019171352A3 WO 2019171352 A3 WO2019171352 A3 WO 2019171352A3 IB 2019051915 W IB2019051915 W IB 2019051915W WO 2019171352 A3 WO2019171352 A3 WO 2019171352A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
oxyntomodulin derivative
treating severe
severe non
diabetic obesity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2019/051915
Other languages
French (fr)
Other versions
WO2019171352A2 (en
Inventor
Mahesh N. Samtani
Gary MEININGER
Penny Renee FLECK
Maria ALBA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of WO2019171352A2 publication Critical patent/WO2019171352A2/en
Publication of WO2019171352A3 publication Critical patent/WO2019171352A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Disclosed herein are methods of treating severe non-diabetic obesity with an oxyntomodulin derivative conjugate administered once weekly at a dose of about 5 mg to about 10 mg. The oxyntomodulin derivative conjugate comprises an oxyntomodulin derivative comprising the amino acid sequence of SEQ ID NO: 2 and having a ring formation between residues 16 and 20; an IgG4 Fc region; and a polyethylene glycol, wherein the polyethylene glycol covalently links the oxyntomodulin derivative and the IgG4 Fc region.
PCT/IB2019/051915 2018-03-08 2019-03-08 Methods of treating severe non-diabetic obesity Ceased WO2019171352A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862640463P 2018-03-08 2018-03-08
US62/640,463 2018-03-08

Publications (2)

Publication Number Publication Date
WO2019171352A2 WO2019171352A2 (en) 2019-09-12
WO2019171352A3 true WO2019171352A3 (en) 2019-11-07

Family

ID=66223762

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2019/051915 Ceased WO2019171352A2 (en) 2018-03-08 2019-03-08 Methods of treating severe non-diabetic obesity

Country Status (1)

Country Link
WO (1) WO2019171352A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101577734B1 (en) 2011-06-17 2015-12-29 한미사이언스 주식회사 A conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof
TWI652071B (en) 2012-11-06 2019-03-01 韓美藥品股份有限公司 Liquid preparation containing protein conjugate of acid modulator and immunoglobulin fragment
KR102418477B1 (en) 2014-12-30 2022-07-08 한미약품 주식회사 Gluagon Derivatives
WO2020128967A2 (en) * 2018-12-19 2020-06-25 Janssen Pharmaceutica Nv Methods of treating severe non-diabetic obesity
EP4154867A4 (en) * 2020-05-22 2025-01-29 Hanmi Pharm. Co., Ltd. LIQUID FORMULATION
BR112022023609A2 (en) * 2020-05-22 2023-02-07 Hanmi Pharm Ind Co Ltd LIQUID FORMULATION OF GLUCAGON, GLP-1 AND GIP TRIGONAL AGONIST LONG-ACTING CONJUGATE
AU2022298841A1 (en) * 2021-06-25 2024-01-25 Innovent Biologics (Suzhou) Co., Ltd. Use of mazdutide

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012173422A1 (en) * 2011-06-17 2012-12-20 Hanmi Science Co., Ltd. A conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof
WO2014017843A1 (en) * 2012-07-25 2014-01-30 Hanmi Pharm. Co., Ltd. Composition for treating hyperlipidemia comprising oxyntomodulin derivative
WO2014073845A1 (en) * 2012-11-06 2014-05-15 Hanmi Pharm. Co., Ltd. A composition for treating diabetes or diabesity comprising oxyntomodulin analog
WO2016043533A1 (en) * 2014-09-16 2016-03-24 Hanmi Pharm. Co., Ltd. Use of a long acting glp-1/glucagon receptor dual agonist for the treatment of non-alcoholic fatty liver disease

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012173422A1 (en) * 2011-06-17 2012-12-20 Hanmi Science Co., Ltd. A conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof
WO2014017843A1 (en) * 2012-07-25 2014-01-30 Hanmi Pharm. Co., Ltd. Composition for treating hyperlipidemia comprising oxyntomodulin derivative
WO2014073845A1 (en) * 2012-11-06 2014-05-15 Hanmi Pharm. Co., Ltd. A composition for treating diabetes or diabesity comprising oxyntomodulin analog
WO2016043533A1 (en) * 2014-09-16 2016-03-24 Hanmi Pharm. Co., Ltd. Use of a long acting glp-1/glucagon receptor dual agonist for the treatment of non-alcoholic fatty liver disease

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "2017-003616-39: A Randomized, Double-blind Placebo-controlled and Open-label Active-controlled, Parallel-group, Multicenter, Dose-ranging Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Non-diabetic Severely Obese Subjects", 13 March 2018 (2018-03-13), pages 1 - 5, XP055612057, Retrieved from the Internet <URL:https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-003616-39/SE> [retrieved on 20190809] *
ANONYMOUS: "Disposicion N° 05458", 17 July 2017 (2017-07-17), pages 1 - 8, XP055612052, Retrieved from the Internet <URL:http://www.anmat.gov.ar/boletin_anmat/mayo_2017/Dispo_5458-17.pdf> [retrieved on 20190809] *
ANONYMOUS: "HM 12525A - AdisInsight", 14 October 2017 (2017-10-14), pages 1 - 4, XP055612030, Retrieved from the Internet <URL:http://web.archive.org/web/20171014193308/https://adisinsight.springer.com/drugs/800040692> [retrieved on 20190809] *
ANONYMOUS: "International Nonproprietary Names for Pharmaceutical Substances (INN)", WHO DRUG INFORMATION, vol. 31, no. 4, 19 January 2017 (2017-01-19), pages 635 - 754, XP055612042 *
ANONYMOUS: "NCT03486392: A Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Non-diabetic Severely Obese Participants", 30 March 2018 (2018-03-30), pages 1 - 9, XP055612060, Retrieved from the Internet <URL:https://clinicaltrials.gov/ct2/history/NCT03486392?V_1=View#StudyPageTop> [retrieved on 20190809] *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 8 January 2017 (2017-01-08), ANONYMOUS: "Efinopegdutide", XP002793492, retrieved from STN Database accession no. 2055640-93-0 *
J KANG ET AL: "791: The ultra-long acting LAPSGLP/GCGdual agonist,HM12525A, demonstrated safety and prolonged pharmacokinetics in healthy volunteers: a phase 1 first-in-human study", ABSTRACTS OF 51ST EASD ANNUAL MEETING, vol. 58, 1 September 2015 (2015-09-01), pages S380 - S381, XP055611972 *
JAHOON KANG ET AL: "The ultra-long acting LAPS GLP/GCG dual agonist, HM12525A, demonstrated safety and prolonged pharmacokinetics in healthy volunteers: a phase 1 first-in-human study PS-069-791 REFERENCES", 23 September 2015 (2015-09-23), pages 1 - 2, XP055612020, Retrieved from the Internet <URL:http://www.hanmipharm.com/ehanmi/img/rnd/2015_EASD_(HM12525A).pdf> [retrieved on 20190809] *
JI-HEE HA ET AL: "Immunoglobulin Fc Heterodimer Platform Technology: From Design to Applications in Therapeutic Antibodies and Proteins", FRONTIERS IN IMMUNOLOGY, vol. 7, 6 October 2016 (2016-10-06), pages 1 - 16, XP055377975, DOI: 10.3389/fimmu.2016.00394 *
S JUNG ET AL: "790: Potent weight loss mechanism and improvement of NASH by the long-acting GLP-1/glucagon receptor dual agonist HM12525A", ABSTRACTS OF 51ST EASD ANNUAL MEETING, vol. 58, 1 September 2015 (2015-09-01), pages S380 - S381, XP055611969, DOI: 10.1007/s00125-015-3687-4 *
SY JUNG ET AL: "A Novel Long-Acting GLP-1/Glucagon Dual Receptor Agonist: Potent Weight Loss Mechanism and Improvement of NASH by HM12525A", 75TH ANNUAL SCIENTIFIC SESSIONS OF THE AMERICAN DIABETES ASSOCIATION, 6 June 2015 (2015-06-06), pages 1, XP055611892 *

Also Published As

Publication number Publication date
WO2019171352A2 (en) 2019-09-12

Similar Documents

Publication Publication Date Title
WO2019171352A3 (en) Methods of treating severe non-diabetic obesity
CN110740754A (en) kinds of anti-mesothelin antibody and antibody drug conjugate thereof
US20250302979A1 (en) Antibody-oligonucleotide conjugate and antibody-peptide-oligonucleotide conjugate compositions and methods of inducing exon skipping
US11779653B2 (en) Multi-armed polyrotaxane platform for protected nucleic acid delivery
NZ705384A (en) Composition for treating hyperlipidemia comprising oxyntomodulin derivative
NZ708105A (en) A composition for treating diabetes or diabesity comprising oxyntomodulin analog
MX340015B (en) Pharmaceutical composition for treatment and/or prevention of cancer.
MX342291B (en) Pharmaceutical composition for treatment and/or prevention of cancer.
MX340016B (en) Pharmaceutical composition for treatment and/or prevention of cancer.
JP2022037244A (en) Multivalent fragment of antibody 3E10 and how to use it
JP2019104738A (en) Cd20-binding immunotoxins for inducing cellular internalization and methods of use
WO2011149964A3 (en) Methods for treating or preventing vascular graft failure
NZ591130A (en) Compositions comprising a PD-1 antagonists and cyclophosphamide and methods of use thereof
WO2007097903A3 (en) Hiv fusion inhibitor peptides with improved biological properties
CN105142663A (en) Pharmaceutical compositions containing albumin-binding arginine deiminase for targeted cancer therapy
TW201818075A (en) Conditionally active polypeptides and methods of generating them
WO2009059309A2 (en) Furin-cleavable peptide linkers for drug-ligand conjugates
Zhang et al. Drug-free macromolecular therapeutics: Impact of structure on induction of apoptosis in Raji B cells
CR20200145A (en) Nti-egfr antibody drug conjugates (adc) and uses thereof
JP2004533250A5 (en)
WO2023081482A9 (en) Combination of a bile acid and a phenyl butyrate compound for the treatment of neurodegenerative diseases
CN102348463B (en) Use of interleukin-22 in preventing and/or treating multiple organ dysfunction syndrome (MODS)
JP7418756B2 (en) CD38 binding protein containing deimmunized Shiga toxin A subunit effector
WO2022010939A3 (en) Peptides and methods of using the same
WO2020128967A3 (en) Efinopegdutide for use in the treatment of severe non-diabetic obesity

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19718449

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19718449

Country of ref document: EP

Kind code of ref document: A2